[go: up one dir, main page]

AR055145A1 - Derivados de pirazolona - Google Patents

Derivados de pirazolona

Info

Publication number
AR055145A1
AR055145A1 ARP060103758A ARP060103758A AR055145A1 AR 055145 A1 AR055145 A1 AR 055145A1 AR P060103758 A ARP060103758 A AR P060103758A AR P060103758 A ARP060103758 A AR P060103758A AR 055145 A1 AR055145 A1 AR 055145A1
Authority
AR
Argentina
Prior art keywords
alkyl
phenyl
bicyclo
tetrahydro
methyl
Prior art date
Application number
ARP060103758A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR055145A1 publication Critical patent/AR055145A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C07D231/26—1-Phenyl-3-methyl-5- pyrazolones, unsubstituted or substituted on the phenyl ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Pueden utilizarse en forma de composiciones farmacéuticas, para su uso en trastornos metabolicos. Reivindicacion 1: Compuestos de la formula (1) en la que R1 es hidrogeno, alquilo, cicloalquilo, cicloalquilalquilo, aralquilo, haloalquilo, arilo, piridinilmetilo o heterociclilo; y con la condicion de que, en el caso de que R1 sea hidrogeno, entonces R3 sea adamantanilo o adamantilo, sustituido de una a tres veces por sustituyentes elegidos con independencia entre sí entre alquilo, hidroxi, halogeno y haloalquilo; R2 es hidrogeno, alquilo, cicloalquilo, arilo, aralquilo, benzotiazolilo, biciclo(2.2.1)heptilo o biciclo(2.2.2)octilo, en los que biciclo(2.2.1)heptilo y biciclo(2.2.2)octilo están opcionalmente sustituidos de una a tres veces por sustituyentes elegidos con independencia entre sí entre alquilo, hidroxi, halogeno y haloalquilo; o R1 y R2 junto con los átomos de nitrogeno a los que están unidos forman pirazolidina, hexahidro-piridazina, (1,2)-diazepano o 2,3,4,5- tetrahidro-1H-benzo(c)(1,2)diazepina, en los que la pirazolidina, hexahidro-piridazina, (1,2)diazepano y 2,3,4,5- tetrahidro-1H-benzo(c)(1,2)diazepina están opcionalmente sustituidos de una a tres veces por grupos alquilo; o R1 y R4, juntos, forman - (CH2) m-; m es el numero 3, 4, 5 o 6; R3 es ciclopropilo, arilciclopropilo, isopropilo, tert-butilo, adamantanilo o biciclo(2.2.2)octilo, en los que adamantanilo y biciclo(2.2.2)octilo están opcionalmente sustituidos de una a tres veces por sustituyentes elegidos con independencia entre sí entre alquilo, hidroxi, halogeno y haloalquilo; R4 es hidrogeno, alquilo, cicloalquilo, ariloxialquilo, alquilcarbonilaminoariloxialquilo, alquiloxialquilo, arilo, aralquilo, haloalquilo o halocicloalquilo; o R3 y R4, juntos, forman -(CH2)n-; n es el numero3, 4,5 o 6; y sales y ésteres farmacéuticamente aceptables de los mismos; con la condicion de que, en el caso de que R3 y R4, juntos, formen -(CH2)n-, entonces R1 sea alquilo y no sea hidrogeno o alquilo; y con la condicion de que, en el caso de que R4 sea hidrogeno o alquilo, entonces R3 no sea isopropilo; y con la condicion de que se excluyan la 3-ciclopropil-4-isopropil-2-metil-1-fenil-3-pirazolin-5-ona; 1,2-dihidro-5- metil-4-triciclo(3.3.1.13,7)dec-1- il-3H-pirazol-3-ona; 1,2,3,4,6,7,8,9-octahidro-10H,12H-indazolo(1,2-a)indazol-10,12-diona; 1,2,4,5,6,7-hexahidro-1-metil-2-fenil-3H-indazol-3- ona; 1,4,5,6-tetrahidro-1-metil-2-fenil-3(2H)-ciclopentapirazolona; 1,4,5,6-tetrahidro-1-bencil-2-fenil-3(2H)-ciclopentapirazolona; 1,4,5,6- tetrahidro-1-etil-2-(4-metil)-fenil-3(2H)-ciclopentapirazolona; 1,4,5,6-tetrahidro-1-etil-2-fenil-3(2H)-ciclopentapirazolona; y 1,4,5,6,7,8- hexahidro-1-metil-2-fenil-3(2H)- cicloheptapirazolona.
ARP060103758A 2005-08-31 2006-08-29 Derivados de pirazolona AR055145A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05107970 2005-08-31

Publications (1)

Publication Number Publication Date
AR055145A1 true AR055145A1 (es) 2007-08-08

Family

ID=37729936

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103758A AR055145A1 (es) 2005-08-31 2006-08-29 Derivados de pirazolona

Country Status (23)

Country Link
US (1) US7652057B2 (es)
EP (1) EP1924562A2 (es)
JP (1) JP5073664B2 (es)
KR (1) KR100982088B1 (es)
CN (1) CN101243050B (es)
AR (1) AR055145A1 (es)
AU (1) AU2006286646B2 (es)
BR (1) BRPI0615039A2 (es)
CA (1) CA2618840C (es)
CR (1) CR9703A (es)
EC (1) ECSP088229A (es)
HK (1) HK1123295A1 (es)
IL (1) IL189186A0 (es)
MA (1) MA29775B1 (es)
MX (1) MX2008002583A (es)
MY (1) MY145464A (es)
NO (1) NO20080554L (es)
NZ (1) NZ565536A (es)
RU (1) RU2407737C2 (es)
TW (1) TWI332949B (es)
UA (1) UA90742C2 (es)
WO (1) WO2007025880A2 (es)
ZA (1) ZA200801444B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009318098B2 (en) * 2008-11-20 2015-07-16 Northwestern University Treatment of amyotrophic lateral sclerosis
US9428467B2 (en) 2008-11-20 2016-08-30 Northwestern University Selective calcium channel antagonists
US9145424B2 (en) 2008-11-20 2015-09-29 Northwestern University Treatment of amyotrophic lateral sclerosis
BRPI1010604A2 (pt) * 2009-05-22 2017-05-23 Abbott Gmbh & Co Kg moduladores dos receptores 5-ht e métodos de uso dos mesmos
WO2011051958A1 (en) 2009-10-30 2011-05-05 E.I. Du Pont De Nemours And Company Fungicidal pyrazolones
CN103002735B (zh) * 2010-05-21 2015-05-20 Abbvie公司 5-ht受体的调节剂和其使用方法
EP2881388A1 (en) 2013-12-09 2015-06-10 Basf Se Pyrazolone compounds having herbicidal activity
EP2881387A1 (en) 2013-12-09 2015-06-10 Basf Se Pyrazolone compounds having herbicidal activity
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
WO2019048989A1 (en) 2017-09-08 2019-03-14 Pi Industries Ltd. NOVEL FUNGICIDE HETEROCYCLIC COMPOUNDS
WO2019048988A1 (en) 2017-09-08 2019-03-14 Pi Industries Ltd. NOVEL FUNGICIDE HETEROCYCLIC COMPOUNDS
WO2020210922A1 (es) * 2019-04-17 2020-10-22 Pontificia Universidad Católica De Chile Derivados de adamantiloxadiazoles y sus solvatos, hidratos y sales farmacéuticamente aceptables del mismo, composición farmacéutica que los comprende, proceso de síntesis, útiles como inhibidores efectivos y selectivos de la actividad reductasa de la enzima 11-beta deshidrogenasa tipo 1 (11β-hsd1)
CN113527207B (zh) * 2020-04-22 2023-06-06 常州强力电子新材料股份有限公司 乙氧基/丙氧基改性的吡唑啉有机物、其应用、光固化组合物及光刻胶
CN112375072B (zh) * 2020-09-28 2021-05-28 上海长征富民金山制药有限公司 吡唑啉酮衍生物、注射剂及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2731473A (en) * 1956-01-17 New pyrazolone derivatives
DE668628C (de) * 1935-12-08 1938-12-07 Beiersdorf & Co A G P Verfahren zur Darstellung von Alkyl- und Aralkylabkoemmlingen der 3,4-Cyclotetramethylen-1-aryl-5-pyrazolone
JPS609752B2 (ja) * 1979-11-09 1985-03-12 東邦新薬株式会社 新規な２−アセトキシベンズアミド誘導体、その製法及びそれを有効成分とする医薬
DE4415484A1 (de) 1994-05-03 1995-11-09 Basf Ag Verfahren zur Herstellung von 1-(Het)aryl-3-hydroxy-pyrazolen
US5663365A (en) * 1996-10-29 1997-09-02 Japan Hydrazine Co., Ltd. Process for the preparation of pyrazolones
DK0870757T3 (da) * 1997-04-10 2002-07-15 Pfizer Fluorsubstituerede adamantanderivater
TW536387B (en) * 1998-04-23 2003-06-11 Sumitomo Chemical Co Pyrazolinone compound
AU782330B2 (en) * 1999-08-31 2005-07-21 Kissei Pharmaceutical Co. Ltd. Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
JP4035052B2 (ja) * 2000-12-28 2008-01-16 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体及びその医薬用途
WO2004024705A1 (ja) * 2002-09-10 2004-03-25 Takeda Pharmaceutical Company Limited ５員複素環化合物
PL377426A1 (pl) 2002-12-19 2006-02-06 Bristol-Myers Squibb Company Podstawione tricykliczne gamma-karboliny jako agoniści i antagoniści receptora serotoninowego
GB0306718D0 (en) * 2003-03-24 2003-04-30 Sterix Ltd Compound
WO2005016877A2 (en) * 2003-08-07 2005-02-24 Merck & Co., Inc. Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1

Also Published As

Publication number Publication date
KR100982088B1 (ko) 2010-09-13
EP1924562A2 (en) 2008-05-28
CA2618840A1 (en) 2007-03-08
CA2618840C (en) 2011-07-05
MA29775B1 (fr) 2008-09-01
KR20080031482A (ko) 2008-04-08
RU2008111971A (ru) 2009-10-10
NZ565536A (en) 2011-03-31
BRPI0615039A2 (pt) 2011-04-26
WO2007025880A3 (en) 2007-05-03
ECSP088229A (es) 2008-03-26
ZA200801444B (en) 2008-12-31
CR9703A (es) 2008-02-20
RU2407737C2 (ru) 2010-12-27
US20070049574A1 (en) 2007-03-01
CN101243050A (zh) 2008-08-13
MX2008002583A (es) 2008-03-18
JP2009506089A (ja) 2009-02-12
IL189186A0 (en) 2008-06-05
CN101243050B (zh) 2012-07-04
MY145464A (en) 2012-02-15
UA90742C2 (en) 2010-05-25
AU2006286646B2 (en) 2010-09-23
TWI332949B (en) 2010-11-11
AU2006286646A1 (en) 2007-03-08
WO2007025880A2 (en) 2007-03-08
TW200740764A (en) 2007-11-01
HK1123295A1 (en) 2009-06-12
NO20080554L (no) 2008-03-14
US7652057B2 (en) 2010-01-26
JP5073664B2 (ja) 2012-11-14

Similar Documents

Publication Publication Date Title
AR055145A1 (es) Derivados de pirazolona
CY1118292T1 (el) Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
UY33921A (es) Oxazinopteridinas y oxazinoptiridinonas n-sustituidas
NI201000085A (es) Derivados bis - (sulfonilamino) en terapia 066.
UY31193A1 (es) Derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]-piridazina, su preparasción y su aplicación en terapéutica
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
UY31546A1 (es) Derivados bis-(sulfonilamino) en terapia 205
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
CR9587A (es) Derivados de piridazina
ECSP077424A (es) Derivados de quinuclidina y su uso como antagonistas del receptor muscarínico m3
PA8795301A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
ECSP088971A (es) Ligandos 101 de los receptores nicotínicos de acetilcolina
UY29420A1 (es) Derivados de 2-piridona,composiciones que los contienen, procesos de preparación y aplicación
AR063118A1 (es) Derivados de sulfonamida-piperidina composiciones farmaceuticas que los contienen y usos en enfermedades y trastornos inflamatorios alergicos y respiratorios
PA8783601A1 (es) Derivados de piperidina/piperazina
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
AR073077A1 (es) Uso de dabigatran. compuesto. composicion farmaceutica-
BRPI0614493B8 (pt) uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, processo para a preparação de um composto e o referido composto
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
UY31457A1 (es) Derivados acidos de cicloalquilamino
ECSP109900A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas
AR078164A1 (es) Derivados de isoxazolidina, proceso para preparar dichos compuestos y composiciones farmaceuticas que los comprenden
AR077534A1 (es) Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5
AR063027A1 (es) Derivados de sulfonamida

Legal Events

Date Code Title Description
FB Suspension of granting procedure